BR112015027400A2 - Anticorpos capazes de se ligar especificamente ao her2 - Google Patents
Anticorpos capazes de se ligar especificamente ao her2Info
- Publication number
- BR112015027400A2 BR112015027400A2 BR112015027400A BR112015027400A BR112015027400A2 BR 112015027400 A2 BR112015027400 A2 BR 112015027400A2 BR 112015027400 A BR112015027400 A BR 112015027400A BR 112015027400 A BR112015027400 A BR 112015027400A BR 112015027400 A2 BR112015027400 A2 BR 112015027400A2
- Authority
- BR
- Brazil
- Prior art keywords
- her2
- antibodies
- present
- trastuzumab
- epitope
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
ANTICORPOS CAPAZES DE SE LIGAR ESPECIFICAMENTE AO HER2. A presente invenção se refere a anticorpos ao HER2 (Receptor 2 de Fator de Crescimento Epidérmico Humano) para prevenir ou tratar cânceres. Os anticorpos da presente invenção se ligam especificamente ao HER2 superexpresso em células cancerosas (em particular, células de câncer de mama e câncer de estômago), especificamente a um epítopo sobre HER2 que é diferente do epítopo para o trastuzumabe. As sequências de CDR dos presentes anticorpos exibem baixa similaridade com sequências de CDR de anticorpos HER2 conhecidos publicamente, significando que as sequências de CDR são únicas. Os anticorpos da presente invenção, em combinação com o trastuzumabe, matam as células cancerosas com citotoxicidade significativamente aprimorada e, portanto, são muito eficazes em terapia de câncer (particularmente, câncer de mama e câncer de estômago). Sem pretender ficar limitado pela teoria, as eficácias aprimoradas da terapia combinada significam que os anticorpos da presente invenção se ligam a um epítopo sobre HER2 que é diferente do epítopo para o trastuzumabe e inibem o HER2 de um modo cooperativo com o trastuzumabe.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2013-0055912 | 2013-05-16 | ||
| KR20130055912 | 2013-05-16 | ||
| PCT/KR2014/004317 WO2014185704A1 (ko) | 2013-05-16 | 2014-05-14 | Her2에 특이적으로 결합하는 항체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015027400A2 true BR112015027400A2 (pt) | 2017-08-29 |
| BR112015027400B1 BR112015027400B1 (pt) | 2023-04-25 |
Family
ID=51898619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015027400-5A BR112015027400B1 (pt) | 2013-05-16 | 2014-05-14 | Anticorpo capaz de se ligar especificamente ao her2 ou fragmento de ligação ao antígeno do mesmo, composições farmacêuticas e kit que compreendem os mesmos, bem como uso dos mesmos para prevenir ou tratar um câncer e/ou induzir apoptose |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10174116B2 (pt) |
| EP (1) | EP2998319B1 (pt) |
| JP (2) | JP6234548B2 (pt) |
| KR (1) | KR101453462B1 (pt) |
| CN (1) | CN105164160B (pt) |
| AU (1) | AU2014266118B2 (pt) |
| BR (1) | BR112015027400B1 (pt) |
| CA (1) | CA2910407C (pt) |
| ES (1) | ES2710707T3 (pt) |
| HK (1) | HK1217500A1 (pt) |
| MX (1) | MX368228B (pt) |
| RU (1) | RU2628094C2 (pt) |
| WO (1) | WO2014185704A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104119533B (zh) * | 2010-02-10 | 2018-06-26 | 宇部兴产株式会社 | 聚酰亚胺膜、含它的聚酰亚胺层压体和含它的聚酰亚胺金属层压体 |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| KR101796277B1 (ko) * | 2016-04-12 | 2017-11-13 | 앱클론(주) | 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체 |
| EP3241847A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Her-2 binding antibodies |
| EP3455260B1 (en) * | 2016-05-12 | 2022-07-06 | Agency for Science, Technology and Research | Anti-erbb-2 antibodies and uses thereof |
| CN110709419B (zh) * | 2017-01-06 | 2023-11-28 | 博奥信生物技术（南京）有限公司 | Erbb2抗体及其用途 |
| US11459394B2 (en) * | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| US20210179733A1 (en) * | 2017-11-14 | 2021-06-17 | Green Cross Lab Cell Corporation | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN110790840A (zh) * | 2018-08-01 | 2020-02-14 | 三生国健药业（上海）股份有限公司 | 结合人her2的抗体、其制备方法和用途 |
| KR20200098831A (ko) | 2019-02-13 | 2020-08-21 | 건국대학교 글로컬산학협력단 | 신규한 부위-특이적 항체 절편 플랫폼 |
| US20220204644A1 (en) * | 2019-05-02 | 2022-06-30 | Mab Discovery Gmbh | Combination of her2 antibodies |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| WO1988006630A1 (en) | 1987-03-02 | 1988-09-07 | Genex Corporation | Method for the preparation of binding molecules |
| EP0621340A1 (en) | 1987-03-20 | 1994-10-26 | Creative Biomolecules, Inc. | Product and process for the production and purification of recombinant polypeptides |
| EP0305481B1 (en) | 1987-03-20 | 1993-09-29 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| JPH08504172A (ja) | 1992-06-30 | 1996-05-07 | オンコロジクス，インコーポレイティド | 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法 |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| EP1695986B1 (en) * | 1996-10-18 | 2016-12-14 | Genentech, Inc. | Anti-erb B2 antibodies |
| US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| MXPA06005024A (es) | 2003-11-06 | 2006-07-06 | Pfizer Prod Inc | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer. |
| DK1758610T3 (da) | 2004-05-20 | 2012-10-15 | Zymogenetics Inc | Fremgangsmåder til behandling af cancer ved hjælp af IL-21 og monoklonal antistofterapi |
| KR20150140417A (ko) * | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| PT2511301T (pt) * | 2006-08-04 | 2018-03-08 | Medimmune Ltd | Anticorpos humanos para erbb2 |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| ES2407957T3 (es) | 2007-03-09 | 2013-06-17 | Geron Corporation | Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa |
| WO2011001276A1 (en) | 2009-06-30 | 2011-01-06 | Philogen S.P.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
| CN102167742B (zh) * | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| JP6177231B2 (ja) * | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Ｈｅｒ２に対する二重特異性抗体 |
-
2014
- 2014-05-13 KR KR1020140057321A patent/KR101453462B1/ko active IP Right Grant
- 2014-05-14 AU AU2014266118A patent/AU2014266118B2/en active Active
- 2014-05-14 MX MX2015015110A patent/MX368228B/es active IP Right Grant
- 2014-05-14 JP JP2016508909A patent/JP6234548B2/ja active Active
- 2014-05-14 CN CN201480024152.3A patent/CN105164160B/zh active Active
- 2014-05-14 ES ES14798440T patent/ES2710707T3/es active Active
- 2014-05-14 US US14/781,968 patent/US10174116B2/en active Active
- 2014-05-14 CA CA2910407A patent/CA2910407C/en active Active
- 2014-05-14 RU RU2015146664A patent/RU2628094C2/ru active
- 2014-05-14 EP EP14798440.5A patent/EP2998319B1/en active Active
- 2014-05-14 BR BR112015027400-5A patent/BR112015027400B1/pt active IP Right Grant
- 2014-05-14 WO PCT/KR2014/004317 patent/WO2014185704A1/ko active Application Filing
-
2016
- 2016-05-12 HK HK16105433.6A patent/HK1217500A1/zh unknown
-
2017
- 2017-07-06 JP JP2017132833A patent/JP6487968B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1217500A1 (zh) | 2017-01-13 |
| US20160053011A1 (en) | 2016-02-25 |
| BR112015027400B1 (pt) | 2023-04-25 |
| JP6487968B2 (ja) | 2019-03-20 |
| EP2998319A1 (en) | 2016-03-23 |
| CN105164160B (zh) | 2018-11-30 |
| ES2710707T3 (es) | 2019-04-26 |
| JP2018008954A (ja) | 2018-01-18 |
| RU2628094C2 (ru) | 2017-08-14 |
| CA2910407A1 (en) | 2014-11-20 |
| CA2910407C (en) | 2018-12-11 |
| JP2016518368A (ja) | 2016-06-23 |
| CN105164160A (zh) | 2015-12-16 |
| JP6234548B2 (ja) | 2017-11-22 |
| AU2014266118A1 (en) | 2015-11-12 |
| KR101453462B1 (ko) | 2014-10-23 |
| US10174116B2 (en) | 2019-01-08 |
| WO2014185704A1 (ko) | 2014-11-20 |
| MX2015015110A (es) | 2016-08-11 |
| MX368228B (es) | 2019-09-24 |
| EP2998319A4 (en) | 2017-01-25 |
| EP2998319B1 (en) | 2018-11-28 |
| AU2014266118B2 (en) | 2017-03-30 |
| RU2015146664A (ru) | 2017-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015027400A2 (pt) | Anticorpos capazes de se ligar especificamente ao her2 | |
| IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
| IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
| MX2015017485A (es) | Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis. | |
| HK1219486A1 (zh) | 用於治療癌症的涉及抗密蛋白 的抗體的療法 | |
| HK1213925A1 (zh) | 用於治療癌症的涉及抗密蛋白 抗體的組合療法 | |
| SI2766040T1 (sl) | Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| BR112012030479A2 (pt) | terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1 | |
| NZ630881A (en) | Use of semaphorin-4d binding molecules for treatment of atherosclerosis | |
| NZ625758A (en) | Method for treating breast cancer | |
| RS63738B1 (sr) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
| SI2976360T1 (sl) | Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka | |
| WO2014079931A8 (en) | Cd44v6-derived peptides for treating breast cancers | |
| MY174794A (en) | Anticancer composition | |
| WO2013053034A3 (pt) | Tiazacridinas utilizadas na terapia anticâncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2014, OBSERVADAS AS CONDICOES LEGAIS |